SCHEMBL10134745

SCHEMBL10134745

COC(=O)c1ccc2c(c1)nc(Cl)c1cscc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 4/20 0.59
CSNK2A2 P19784 1/20 0.49
CSNK2B P67870 1/20 0.49
KDM4E B2RXH2 6/20 0.43
ALDH1A1 P00352 6/20 0.43
HSD17B10 Q99714 4/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
RAB9A P51151 1/20 0.43
LCK P06239 1/20 0.43
PABPC1 P11940 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
ALOX15 P16050 2/20 0.42
MEN1 O00255 2/20 0.42
HPGD P15428 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559538 0.80 CSNK2A1 (0.57) CSNK2A1CSNK2A2CSNK2BKDM4EALDH1A1
SCHEMBL1452612 0.79 CSNK2A1 (0.54) CSNK2A1CSNK2A2CSNK2B
SCHEMBL629013 0.79 CSNK2A2 (0.71) CSNK2A1CSNK2A2CSNK2B
SCHEMBL2690184 0.79 CSNK2A2 (0.68) CSNK2A1CSNK2A2CSNK2B
SCHEMBL2804216 0.79 CSNK2A1 (0.56) CSNK2A1CSNK2A2CSNK2BKDM4EALDH1A1
SCHEMBL10134828 0.77 CSNK2A1 (0.53) CSNK2A1CSNK2A2CSNK2BKDM4EALDH1A1
SCHEMBL10134833 0.77 CSNK2A1 (0.56) CSNK2A1KDM4EHTTSMN1; SMN2RAB9A
SCHEMBL27375344 0.76 CSNK2A1 (0.63) CSNK2A1CSNK2A2CSNK2BKDM4EALDH1A1
SCHEMBL30133943 0.76 CSNK2A1 (0.56) CSNK2A1CSNK2A2CSNK2BKDM4EALDH1A1
SCHEMBL5349000 0.76 CSNK2A1 (0.56) CSNK2A1CSNK2A2CSNK2BKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.